Work

Topical Ruxolitinib for Immune Checkpoint Inhibitor–Induced Vitiligo

Year: 2026

Type: article

Abstract: The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Source: International Journal of Dermatology

DOI: 10.1111/ijd.70367

Authors: Federico Venturi, Ina Sotiri, Barbara Melotti, Monika Fida, Emi Dika

Institutions: IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna, Mother Teresa Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7131867464

FWCI:

Cites:

Cited by:

Related to: